Pfizer has included the three-year interim data from the postmenopausal evaluation and risk-reduction with lasofoxifene (PEARL) study in the current new drug application (NDA). Fablyn (lasofoxifene tartrate), formerly
Inspire has said that it is terminating the agreement in its entirety, and as a result, it will be no longer responsible for the development and commercialization of
Thelin (sitaxentan sodium) is indicated for improving exercise capacity in pulmonary arterial hypertension (PAH) patients classified as World Health Organization (WHO) functional class III. Efficacy has been shown
In the non-inferiority study comparing risedronate 150mg once monthly to risedronate 5mg daily, increases in lumbar spine bone mineral density (BMD) at one year were similar for patients
The new offices will house the primary business operations of Zonda, including the office of Vera Leonard who serves as president and CEO of both Zonda and CLX
The company has also entered into a financial advisory agreement with EastGate Financial to provide consulting and advisory services with respect to establishing an office in New York,
The phase I/II study will be conducted at sites in Belgium, France and Spain and will enroll up to 30 B-cell chronic lymphocytic leukaemia (B-CLL) patients who have
Following the approval of the investigational new drug (IND) application, Diamyd plans to initiate a Phase I clinical study. The trial will be designed as a dose-escalation study
The company has said that the clinical trial successfully met all objectives and that BIO 300 was well tolerated at all dose levels which were studied. The completion
Breckenridge has completed a shared 180-day exclusivity period and will immediately launch oxcarbazepine tablets 150mg, 300mg, and 600mg. Oxcarbazepine tablets are AB rated to Trileptal which is being
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.